Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

现代表型药物发现：从化学生物学到治疗学

• 批准号: 10468419
• 负责人: Thale Cross Jarvis
• 金额: $ 1.72万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-15 至 2023-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468419
• 关键词: 3-Dimensional; Academia; Address; Area; Artificial Intelligence; Biological; Biological Assay; Biological Models; Biology; CRISPR/Cas technology; Cells; Chemicals; Chemistry; Clinical; Collaborations; Colorado; Communities; Data Science; Discipline; Educational workshop; Evolution; Fostering; Genes; Goals; Health; Human; Image; Industry; Knowledge; Learning; Machine Learning; Mentors; Methodology; Modeling; Modernization; Outcome; Phenotype; Physiological; Renaissance; Research; Research Personnel; Science; Scientist; Technology; Therapeutic; Translating; Work; base; career; cheminformatics; clinical practice; drug discovery; human disease; improved; induced pluripotent stem cell; innovation; interest; meetings; new technology; novel; posters; pre-clinical; programs; recruit; screening; small molecule; success; symposium; translational impact

ABSTRACT Support is requested for a Keystone Symposia conference entitled Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics, organized by Drs. Bridget Wagner, Neil Carragher, Jeremy Jenkins and Laura Kiessling. The conference will be held in Denver, Colorado from May 22-25, 2022. Phenotypic Drug Discovery (PDD) as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This conference will bring together researchers performing or interested in phenotypic drug discovery from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. This conference aims to share information and best practices in new PDD technologies, biological models, and human disease areas, as well as foster collaborative discussions across academia and industry. Additionally, this conference program will address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). It is anticipated that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.

抽象的 请求支持题为“现代表型药物发现：来自”的 Keystone Symposia 会议 从化学生物学到治疗学，由布里奇特·瓦格纳 (Bridget Wagner)、尼尔·卡拉格 (Neil Carragher)、杰里米·詹金斯 (Jeremy Jenkins) 博士和 Laura Kiessling。会议将于 2022 年 5 月 22 日至 25 日在科罗拉多州丹佛举行。 表型药物发现（PDD）作为药物发现和化学生物学的一种方法一直在发展 学术界和工业界的动力和兴奋新技术平台的融合。 （例如，诱导多能干细胞、CRISPR-Cas9 基因编辑、3D 生物学、高级成像）与其他 化学信息学、机器学习和人工智能等学科带来了令人兴奋的结果 PDD 的复兴将汇集对表型感兴趣的研究人员。 尽管 PDD 的现代进展跨越了学术界和工业界。 和工业部门，很少有以非商业药物发现为重点的会议可供 社区，Keystone 研讨会计划是该主题的首要论坛。 分享新的 PDD 技术、生物模型和人类疾病领域的信息和最佳实践， 此外，本次会议还促进学术界和工业界的合作讨论。 计划将解决该领域的几个关键障碍：如何提高生理相关性 表型模型和识别表型目标并了解化合物的作用机制 （MoA）预计与会者将在离开时重新认识表型策略。 化学生物学的各个领域，并且通过扩大我们的集体努力，该领域将得到推进 突破改进的检测模型和尖端 MoA 技术的界限。